Researchers pursued a flu vaccine that would not need yearly updates. The strategy aims immunity at a conserved part of the virus that mutates little. Early trials tested whether it could offer broad, lasting protection.
Aim at the stalk
The target shifts. Instead of the variable head, vaccines target the stable stalk. Conservation is the key.
Broad protection
Breadth is the goal. Antibodies to the stalk may cover many strains. Yearly shots could fade.
mRNA delivery
Platforms converge. Some candidates use the mRNA technology proven in COVID. Design is flexible.
Early trials
Testing began. First-in-human studies assessed safety and response. Data are preliminary.
A hard problem
History is humbling. Universal flu vaccines have long proved elusive. Skepticism is healthy.
High stakes
The prize is large. A durable vaccine would ease a global burden. Effort is intense.
The bottom line
A universal flu strategy targets the virus’s conserved stalk to seek broad, lasting protection. mRNA platforms aid the effort. Early trials are underway for a long-elusive goal.
